FDA Clearance Tracker · P960009-S219
MEDTRONIC DBS THERAPY FOR EPILEPSY
Last checked: Nov 20, 2026Latest source record: Apr 27, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Apr 27, 2018
Approved
Time to decision
1,158 days
Received Feb 24, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P960009-S219
- Device name
- MEDTRONIC DBS THERAPY FOR EPILEPSY
- Applicant
- Medtronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Feb 24, 2015
- Decided
- Apr 27, 2018
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P960009
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to expand the indications for the Medtronic DBS system to include Epilepsy. Bilateral stimulation of the anterior nucleus of the thalamus (ANT) using the Medtronic DBS System for Epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to three or more antiepileptic medications.The Medtronic DBS System for Epilepsy has demonstrated safety and effectiveness for patients who average six or more seizures per month over the three most recent months prior to implant of the DBS system (with no more than 30 days between seizures). The Medtronic DBS System for Epilepsy has not been evaluated in patients with less frequent seizures.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.